Skip to main content

Advertisement

Table 3 Treatment modalities of patients with localized PG-DLBCL

From: Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution

Treatment N 5-year RFS P value 5-year OS P value
Radical surgery 74 88.5 ± 4.4 % 0.004 87.7 ± 4.8 % 0.004
Alleviate surgery 27 69.5 ± 9.7 % 72.3 ± 9.7 %
Radical surgery and chemotherapy with Rituximab 44 93.8 ± 4.3 % 0.302 93.3 ± 4.6 % 0.333
Radical surgery and chemotherapy without Rituximab 21 88.2 ± 7.8 % 88.2 ± 7.8 %
Alleviate surgery and chemotherapy with Rituximab 16 92.9 ± 6.9 % 0.002 91.7 ± 8.0 % 0.001
Alleviate surgery and chemotherapy without Rituximab 8 58.3 ± 18.6 % 71.4 ± 17.1 %
  1. Abbreviations: PG-DLBCL primary gastrointestinal diffuse large B cell lymphoma, RFS relapse-free survival, OS overall survival